Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 4/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | ADH4 | P08319 | 1/20 | 0.33 |
| ▸ | ADH7 | P40394 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21160913 | 0.79 | CA1 (0.36) | CA1ACE2FDPSSPHK1LMNA | |
| SCHEMBL19788315 | 0.77 | CA2 (0.35) | FDPSSPHK1LMNALAP3FFAR1 | |
| SCHEMBL26457162 | 0.76 | CA2 (0.38) | LMNALAP3 | |
| SCHEMBL26347301 | 0.74 | LAP3 (0.33) | FDPSSPHK1LMNALAP3 | |
| SCHEMBL25941209 | 0.73 | CA2 (0.35) | CA1 | |
| SCHEMBL24978535 | 0.72 | ACE2 (0.37) | CA1ACE2FDPSSPHK1LMNA | |
| SCHEMBL18927449 | 0.72 | CA1 (0.36) | CA1FDPSTSHR | |
| SCHEMBL26729197 | 0.71 | CA2 (0.36) | FDPSSPHK1LMNALAP3FFAR4 | |
| SCHEMBL22623298 | 0.70 | LMNA (0.40) | FDPSSPHK1LMNALAP3FFAR1 | |
| SCHEMBL26457178 | 0.70 | CA2 (0.39) | FDPSLMNALAP3FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787430-B2 | Hemoglobin modifier compounds and uses thereof | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190330181-A1 | HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330181-A1 | HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF | HBB, HBG1, HBG2 | CA1 2741/4885ACE2 2593/4885FDPS 604/4885 |
| US-10787430-B2 | Hemoglobin modifier compounds and uses thereof | HBB, HBG1, HBG2 | CA1 2741/4885ACE2 2593/4885FDPS 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.